|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 2121 K Street, NW, Suite 325 |
Address2 |
|
City | Washington |
State | DC |
Zip Code | 20037 |
Country | USA |
3. Principal place of business (if different than line 2)
City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 1967-12
|
||||||||
|
6. House ID# 317210000
|
TYPE OF REPORT | 8. Year | 2020 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Lupe Gonzales Jr |
Date | 10/2/2020 2:43:56 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ALC
16. Specific lobbying issues
Opioids, pain management
Federal funding for Substance Use Disorder treatments
H.R.2281-Easy Medication Access and Treatment (MAT) for Opioid Addiction Act
H.R.2482-Mainstreaming Addiction Treatment Act of 2019
H.R.2569-Comprehensive Addiction Resources Emergency Act of 2019
S.1365-Comprehensive Addiction Resources Emergency Act of 2019
S.2074-Mainstreaming Addiction Treatment Act of 2019
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Laura |
Wooster |
|
Associate Executive Director, Public Affairs & Washington DC Office |
|
Brad |
Gruehn |
|
Congressional Affairs Director |
|
Ryan |
McBride |
|
Senior Congressional Lobbyist |
|
Jeanne |
Slade |
|
Director, NEMPAC & ACEP Grassroots Advocacy |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
P.L.116-94-Further Consolidated Appropriations Act, 2020
P.L.116-123-Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020
P.L.116-127-Families First Coronavirus Response Act
P.L.116-136-Coronavirus Aid, Relief, and Economic Security (CARES) Act
Federal funding to implement MISSION ZERO program
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Laura |
Wooster |
|
Associate Executive Director, Public Affairs & Washington DC Office |
|
Brad |
Gruehn |
|
Congressional Affairs Director |
|
Ryan |
McBride |
|
Senior Congressional Lobbyist |
|
Jeanne |
Slade |
|
Director, NEMPAC & ACEP Grassroots Advocacy |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CSP
16. Specific lobbying issues
H.R.501-Poison Center Network Enhancement Act of 2019
H.R.1309-Workplace Violence Prevention for Health Care and Social Service Workers Act
S.851-Workplace Violence Prevention for Health Care and Social Service Workers Act
S.1199-Poison Center Network Enhancement Act of 2019
S.3143-Magnet Injury Prevention Act
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Laura |
Wooster |
|
Associate Executive Director, Public Affairs & Washington DC Office |
|
Brad |
Gruehn |
|
Congressional Affairs Director |
|
Ryan |
McBride |
|
Senior Congressional Lobbyist |
|
Jeanne |
Slade |
|
Director, NEMPAC & ACEP Grassroots Advocacy |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code DIS
16. Specific lobbying issues
H.R.2550-Prevent Blood Loss with Emergency Equipment Devices Act of 2019
S.3346-Prevent Blood Loss with Emergency Equipment Devices Act of 2020
Access to emergency medical supplies (including Personal Protective Equipment, COVID-19 tests, ventilators, and medications) during COVID-19 national emergency
Implementation of the Defense Production Act during the COVID-19 national emergency
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Laura |
Wooster |
|
Associate Executive Director, Public Affairs & Washington DC Office |
|
Brad |
Gruehn |
|
Congressional Affairs Director |
|
Ryan |
McBride |
|
Senior Congressional Lobbyist |
|
Jeanne |
Slade |
|
Director, NEMPAC & ACEP Grassroots Advocacy |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code EDU
16. Specific lobbying issues
H.R.1554-Resident Education Deferred Interest (REDI) Act
S.289-Rural Physician Workforce Production Act of 2019
Student loan deferral during the COVID-19 national emergency and loan forgiveness for physicians providing direct care to COVID-19 patients
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Laura |
Wooster |
|
Associate Executive Director, Public Affairs & Washington DC Office |
|
Brad |
Gruehn |
|
Congressional Affairs Director |
|
Ryan |
McBride |
|
Senior Congressional Lobbyist |
|
Jeanne |
Slade |
|
Director, NEMPAC & ACEP Grassroots Advocacy |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code FIR
16. Specific lobbying issues
H.R.8-Bipartisan Background Checks Act of 2019
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Laura |
Wooster |
|
Associate Executive Director, Public Affairs & Washington DC Office |
|
Brad |
Gruehn |
|
Congressional Affairs Director |
|
Ryan |
McBride |
|
Senior Congressional Lobbyist |
|
Jeanne |
Slade |
|
Director, NEMPAC & ACEP Grassroots Advocacy |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Price transparency, out-of-network reimbursement of emergency medical services, surprise medical bills
Opioids, pain management
Federal funding for Substance Use Disorder treatments
Drug Shortages
H.R.501-Poison Center Network Enhancement Act of 2019
H.R.861-End Surprise Billing Act of 2019
H.R.1301-Mental Health Telemedicine Expansion Act
H.R.1309-Workplace Violence Prevention for Health Care and Social Service Workers Act
H.R.1418-Competitive Health Insurance Reform Act of 2019
H.R.1554-Resident Education Deferred Interest (REDI) Act
H.R.1682-Improving Access to Medicare Coverage Act of 2019
H.R.1767-Excellence in Mental Health and Addiction Treatment Expansion Act
H.R.2281-Easy Medication Access and Treatment (MAT) for Opioid Addiction Act
H.R.2328-Reauthorizing and Extending Americas Community Health Act
H.R.2464-End the Cycle of Violence Act of 2019
H.R.2482-Mainstreaming Addiction Treatment Act of 2019
H.R.2519-Improving Mental Health Access from the Emergency Department Act of 2019
H.R.2550-Prevent Blood Loss with Emergency Equipment Devices Act of 2019
H.R.2569-Comprehensive Addiction Resources Emergency Act of 2019
H.R.3107-Improving Seniors Timely Access to Care Act of 2019
H.R.3417-Beneficiary Education Tools, Telehealth, and Extenders Reauthorization Act of 2019
H.R.3502-Protecting People From Surprise Medical Bills Act
H.R.3630-No Surprises Act
H.R.3984-Health Care Safety Net Enhancement Act of 2019
H.R.4861-Effective Suicide Screening and Assessment in the Emergency Department Act of 2019
H.R.4932-Creating Opportunities Now for Necessary and Effective Care Technologies for Health Act of 2019
H.R.5800-Ban Surprise Billing Act
H.R.5826-Consumer Protections Against Surprise Medical Bills Act of 2020
S.289-Rural Physician Workforce Production Act of 2019
S.299-Geriatrics Workforce Improvement Act
S.350-Competitive Health Insurance Reform Act of 2019
S.618-Medicare Choices Empowerment and Protection Act
S.753-Improving Access to Medicare Coverage Act of 2019
S.824-Excellence in Mental Health and Addiction Treatment Expansion Act
S.851-Workplace Violence Prevention for Health Care and Social Service Workers Act
S.1199-Poison Center Network Enhancement Act of 2019
S.1266-Protecting Patients from Surprise Medical Bills Act
S.1334-Improving Mental Health Access from the Emergency Department
S.1350-Good Samaritan Health Professionals Act of 2019
S.1365-Comprehensive Addiction Resources Emergency Act of 2019
S.1531-Stopping The Outrageous Practice of Surprise Medical Bills Act of 2019
S.1895-Lower Health Care Costs Act
S.2074-Mainstreaming Addiction Treatment Act of 2019
S.2741-Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2019
S.3006-Effective Suicide Screening and Assessment in the Emergency Department Act of 2019
S.3143-Magnet Injury Prevention Act
S.3346-Prevent Blood Loss with Emergency Equipment Devices Act of 2020
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Laura |
Wooster |
|
Associate Executive Director, Public Affairs & Washington DC Office |
|
Brad |
Gruehn |
|
Congressional Affairs Director |
|
Ryan |
McBride |
|
Senior Congressional Lobbyist |
|
Jeanne |
Slade |
|
Director, NEMPAC & ACEP Grassroots Advocacy |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code INS
16. Specific lobbying issues
Price transparency, out-of-network reimbursement of emergency medical services, surprise medical bills
H.R.861-End Surprise Billing Act of 2019
H.R.1418-Competitive Health Insurance Reform Act of 2019
H.R.2328-Reauthorizing and Extending Americas Community Health Act
H.R.3107-Improving Seniors Timely Access to Care Act of 2019
H.R.3502-Protecting People From Surprise Medical Bills Act
H.R.3630-No Surprises Act
H.R.5800-Ban Surprise Billing Act
H.R.5826-Consumer Protections Against Surprise Medical Bills Act of 2020
S.350-Competitive Health Insurance Reform Act of 2019
S.1266-Protecting Patients from Surprise Medical Bills Act
S.1531-Stopping The Outrageous Practice of Surprise Medical Bills Act of 2019
S.1895-Lower Health Care Costs Act
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Laura |
Wooster |
|
Associate Executive Director, Public Affairs & Washington DC Office |
|
Brad |
Gruehn |
|
Congressional Affairs Director |
|
Ryan |
McBride |
|
Senior Congressional Lobbyist |
|
Jeanne |
Slade |
|
Director, NEMPAC & ACEP Grassroots Advocacy |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MED
16. Specific lobbying issues
H.R.776-Emergency Medical Services for Children Program Reauthorization Act of 2019
S.1173-Emergency Medical Services for Children Program Reauthorization Act of 2019
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Laura |
Wooster |
|
Associate Executive Director, Public Affairs & Washington DC Office |
|
Brad |
Gruehn |
|
Congressional Affairs Director |
|
Ryan |
McBride |
|
Senior Congressional Lobbyist |
|
Jeanne |
Slade |
|
Director, NEMPAC & ACEP Grassroots Advocacy |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
H.R.861-End Surprise Billing Act of 2019
H.R.1301-Mental Health Telemedicine Expansion Act
H.R.1682-Improving Access to Medicare Coverage Act of 2019
H.R.3417-Beneficiary Education Tools, Telehealth, and Extenders Reauthorization Act of 2019
S.618-Medicare Choices Empowerment and Protection Act
S.753-Improving Access to Medicare Coverage Act of 2019
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Laura |
Wooster |
|
Associate Executive Director, Public Affairs & Washington DC Office |
|
Brad |
Gruehn |
|
Congressional Affairs Director |
|
Ryan |
McBride |
|
Senior Congressional Lobbyist |
|
Jeanne |
Slade |
|
Director, NEMPAC & ACEP Grassroots Advocacy |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TEC
16. Specific lobbying issues
H.R.1301-Mental Health Telemedicine Expansion Act
H.R.3417-Beneficiary Education Tools, Telehealth, and Extenders Reauthorization Act of 2019
H.R.4932-Creating Opportunities Now for Necessary and Effective Care Technologies for Health Act of 2019
S.2741-Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2019
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Laura |
Wooster |
|
Associate Executive Director, Public Affairs & Washington DC Office |
|
Brad |
Gruehn |
|
Congressional Affairs Director |
|
Ryan |
McBride |
|
Senior Congressional Lobbyist |
|
Jeanne |
Slade |
|
Director, NEMPAC & ACEP Grassroots Advocacy |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TOR
16. Specific lobbying issues
H.R.3984-Health Care Safety Net Enhancement Act of 2019
S.1350-Good Samaritan Health Professionals Act of 2019
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Laura |
Wooster |
|
Associate Executive Director, Public Affairs & Washington DC Office |
|
Brad |
Gruehn |
|
Congressional Affairs Director |
|
Ryan |
McBride |
|
Senior Congressional Lobbyist |
|
Jeanne |
Slade |
|
Director, NEMPAC & ACEP Grassroots Advocacy |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
Lobbyist Name | Description of Offense(s) |